Marfan syndrome is a rare genetic disorder that affects the connective tissue and can cause dilation of the aorta and its potential dissection. Currently, pharmacological treatment is mainly based on beta-blockers and angiotensin II receptor antagonists, but their ability to slow the progression of aortopathy is limited.
The review places the focus on oxidative stress, one of the mechanisms involved in the development of the disease. The authors propose that incorporating allopurinol – a drug used for decades to treat gout – could enhance the effectiveness of current treatments by acting precisely on this cellular pathway to exert an antioxidant effect.
The article reviews preclinical studies conducted on different animal models of Marfan syndrome. These studies consistently show that allopurinol is able to reduce oxidative stress, halting the progression of aortic aneurysms and significantly increasing survival in both male and female mice. Gustavo Egea's laboratory is a pioneer in this line of research.
"After almost twenty years without any significant new clinical trials in patients with Marfan syndrome, allopurinol could represent a novel therapeutic opportunity. It is an inexpensive, safe, and well-tolerated drug that could help slow down the progression of the aneurysm and reduce the risk of aortic dissection," Egea highlights.
The authors point out that these results need to be confirmed in human clinical trials. In this regard, the recent designation of allopurinol as an orphan drug for the treatment of Marfan syndrome by the European Medicines Agency (EMA) represents an important step towards facilitating the development of these studies. It is also currently in the evaluation phase with the American Food and Drug Administration (FDA), and international initiatives are already underway to advance towards clinical trials involving patients.
Study of reference
Egea, G., de Souza, R.B., Teixidó-Turà, G. et al. Introducing Allopurinol to the Medical Treatment of Marfan Syndrome: Advantages, Limitations, and Potential Extension to other Aortopathies. Cardiovasc Drugs Ther (2026). https://doi.org/10.1007/s10557-026-07954-8
